Navigation Links
Lionbridge Receives ISO 13485:2003 Certification for Quality Management
Date:3/10/2009

Certification Underscores Lionbridge's Market-Leading Translation Management Program for Life Sciences Organizations Worldwide

WALTHAM, Mass., March 10 /PRNewswire-FirstCall/ -- Lionbridge (Nasdaq: LIOX) today announced that it recently received ISO 13485:2003 certification which verifies quality management systems for medical device companies. This certification expands Lionbridge's dedicated Life Sciences program and enhances the Company's translation management platform to adhere to the rigorous compliance requirements of its medical device clients. Lionbridge was awarded this certification as part of its Life Sciences Center of Excellence initiative, which provides specialized translation services to leading medical device companies, pharmaceutical companies, and contract research organizations around the world.

"This independent certification reflects our proven level of excellence in delivering translation services for medical device and life sciences organizations. As the market leader in translation, Lionbridge is committed to providing the highest levels of quality and service to ensure our clients meet and exceed their customers' expectations while adhering to strict regulatory compliance regulations," said Henri Broekmate, General Manager, Global Language and Content, Lionbridge. "Our clients can take advantage of our superior capabilities in translation and other services with the confidence of knowing our processes comply with the demanding requirements of ISO 13485."

ISO 13485:2003 is an internationally recognized quality standard that outlines particular quality management system requirements tailored to the manufacture of medical devices. ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services. The primary objective of ISO 13485:2003 is to facilitate harmonized medical device regulatory requirements for quality management systems. All requirements of ISO 13485:2003 are specific to organizations providing medical devices, regardless of the type or size of the organization.

Lionbridge's recent ISO 13485:2003 certification complements its existing ISO 9001-2000 certification.

About Lionbridge

Lionbridge Technologies, Inc. (Nasdaq: LIOX) is a leading provider of translation, development and testing services with FY 2008 revenue of $461 million. Lionbridge combines global resources with proven program management methodologies to serve as an outsource partner throughout a client's product and content lifecycle -- from development to translation, testing and maintenance. Global organizations rely on Lionbridge services to increase international market share, speed adoption of global products and content, and enhance their return on enterprise applications and IT system investments. Based in Waltham, Mass., Lionbridge maintains solution centers in 26 countries and provides services under the Lionbridge(R) and VeriTest(R) brands. To learn more, visit http://www.lionbridge.com.

    Contact: Sara Buda
             781-434-6190
             sara.buda@lionbridge.com


'/>"/>
SOURCE Lionbridge Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
2. IDM Pharmas MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
3. Huntington Hospital Cancer Center Receives Outstanding Achievement Designation
4. Takeda Receives New Information on Alogliptin (SYR-322) NDA
5. AED Receives Gates Foundation Grant to Improve Nutrition and Reduce Deaths Among Young Children in Developing Countries
6. MedX Health Receives CE Mark for Laser & Light Products
7. SpectraScience Receives FDA Clearance for Manufacturing Facility
8. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
9. Medical University of South Carolina Hollings Cancer Center Receives National Cancer Institute Designation
10. SynCare Receives Managed Health Services Contract Renewal
11. UIC receives $3 million to study prostate cancer risk factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: